Cargando…

Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis

BACKGROUND: Although the European Medicines Agency and the US Food and Drug Administration have, respectively, approved rivaroxaban for the prevention of recurrent major adverse cardiovascular events in patients with myocardial infarction and stable coronary artery disease, its efficacy and safety i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Cheng, Hang, Yongfu, Zhu, Jianguo, Li, Caiyun, Jiang, Bin, Zhang, Yuzhen, Miao, Liyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803358/ https://www.ncbi.nlm.nih.gov/pubmed/33219708 http://dx.doi.org/10.1002/clc.23514

Ejemplares similares

Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
por: Yuan, Jun
Publicado: (2018)

Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis
por: Wang, Han, et al.
Publicado: (2022)

Rivaroxaban treatment failure: Adding a new case to the list
por: Khan, Fahmi Y.
Publicado: (2020)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
por: Zhou, Dao, et al.
Publicado: (2022)

The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis
por: Mohamed, Mouhand F. H., et al.
Publicado: (2021)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
por: Qian, Jun, et al.
Publicado: (2021)

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
por: Debasu, Zenaw, et al.
Publicado: (2022)

A Ghost in Coronary Artery – Coronary Artery Embolism After Discontinuation of Rivaroxaban in a Patient With Atrial Fibrillation: Case Report and Review of Literature
por: Abbasi, Danish, et al.
Publicado: (2020)

Potential role of rivaroxaban in patients with acute coronary syndrome
por: Fitchett, David H
Publicado: (2012)

Resolution of Extensive Coronary Thrombosis under Rivaroxaban Treatment
por: Yuksel, Murat, et al.
Publicado: (2015)

Added value of contrast echocardiography for the evaluation of multiple giant coronary artery aneurysms with coronary to pulmonary arterial fistulas
por: Zhang, Yiwei, et al.
Publicado: (2022)

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019)

Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories
por: Ishii, Masanobu, et al.
Publicado: (2022)

Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis
por: Mardi, Parham, et al.
Publicado: (2023)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?
por: Bolognese, Leonardo, et al.
Publicado: (2020)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary heart disease and type 2 diabetes mellitus: Cumulative meta‐analysis
por: Xie, Qiuping, et al.
Publicado: (2021)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
por: Chen, Can, et al.
Publicado: (2021)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Use of four‐factor prothrombin complex concentrate for the mitigation of rivaroxaban‐induced bleeding in an emergent coronary artery bypass graft
por: Liu, Michael, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Prevention of radial artery occlusion with rivaroxaban after trans-radial access coronary procedures: The RIVARAD multicentric randomized trial
por: Hammami, Rania, et al.
Publicado: (2023)

Rivaroxaban: Aggravation of superior mesenteric artery thrombosis: case report
Publicado: (2021)

The Associations Between the Polymorphisms of Vitamin D Receptor and Coronary Artery Disease: A Systematic Review and Meta-Analysis
por: Lu, Shuai, et al.
Publicado: (2016)

Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta‐analysis
por: Jiang, Hongcheng, et al.
Publicado: (2021)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
por: Liu, Xiao-Qin, et al.
Publicado: (2023)

Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review
por: Alalawneh, Majdoleen, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study
por: Zekri-Nechar, Khaoula, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
por: Begum, Najida, et al.
Publicado: (2015)

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

Risks and benefits of percutaneous coronary intervention in spontaneous coronary artery dissection
por: Kotecha, Deevia, et al.
Publicado: (2021)

Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting for Chronic Total Occlusion of Coronary Arteries: A Systematic Review and Meta-Analysis
por: Wang, Chenyang, et al.
Publicado: (2023)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1jobbntjpibc67v185lc89ua6q